Quick Answer
BioRestorative Therapies, Inc. reported Stockholders Equity of $356.7 thousand for the year ending 2025.
- BioRestorative Therapies, Inc. showed a decrease of -95.8% in Stockholders Equity from 2024 to 2025.
- This data is from BioRestorative Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: -$6.84 million | Q1 2018: -$7.69 million | Q2 2018: -$9.87 million | Q3 2018: -$8.94 million | Q1 2019: -$7.65 million | Q2 2019: -$8.94 million | Q3 2019: -$12.43 million | Q1 2020: -$17.54 million | Q2 2020: -$14.44 million | Q3 2020: -$15.09 million | Q1 2021: -$2.69 million | Q2 2021: -$3.81 million | Q3 2021: -$4.88 million | Q1 2022: $20.16 million | Q2 2022: $18.59 million | Q3 2022: $17.00 million | Q1 2023: $6.46 million | Q2 2023: $2.64 million | Q3 2023: $10.76 million | Q1 2024: $14.50 million | Q2 2024: $10.80 million | Q3 2024: $9.99 million | Q1 2025: $6.14 million | Q2 2025: $4.85 million | Q3 2025: $2.21 million.
- Historical annual values: Fiscal year 2025: $356.7 thousand | Fiscal year 2024: $8.53 million | Fiscal year 2023: $10.00 million | Fiscal year 2022: $10.29 million | Fiscal year 2021: $21.60 million | Fiscal year 2020: -$1.33 million | Fiscal year 2019: -$12.78 million | Fiscal year 2018: -$8.64 million | Fiscal year 2017: -$6.84 million | Fiscal year 2016: -$5.00 million | Fiscal year 2015: -$3.91 million | Fiscal year 2014: -$6.89 million | Fiscal year 2013: -$6.69 million | Fiscal year 2012: -$5.14 million | Fiscal year 2011: -$3.69 million | Fiscal year 2010: -$744.2 thousand | Fiscal year 2009: -$51.1 thousand | Fiscal year 2008: $0.00.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: